All Articles

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

With a breakthrough oral drug for a rare form of blindness, Belite Bio heads to a key symposium. Can it convince investors it can win a crowded race?

KAYALI's 'Boujee Kitty' wasn't planned in a boardroom but demanded by fans. Explore how a viral joke became the beauty industry's next big thing.

An activist investor group holding 9.1% of Genesco is demanding a leadership shakeup and a massive cash payout, sparking a battle over the retailer's future.

A small tech firm is promising to build video games for a fraction of the cost using AI and the blockchain. Is this a revolution or a speculative gamble?

Refined Energy's move into Newfoundland's rich gold-antimony district is more than just exploration. It's a calculated play on critical mineral supply chains.

The nation's largest physician-owned insurer pulls back the curtain on plastic surgery malpractice, revealing that clinical judgment, not just technical skill, is a top driver of costly claims.

A new $200K award isn't just a grant; it's a strategic bet on systems engineering to fix a diagnostic pathway where 70% of lung cancer cases are found too late.

With only 7% of prop traders ever seeing a payout, one firm is calling for an end to the maze of mismatched rules that defines this booming industry.

A new VTOL drone hunter promises scalable, low-cost defense against aerial swarms. But can SkyDefense's AI-driven interceptor truly disrupt the C-UAS market?

Beyond produce, a new partnership at the Obama Center is growing self-determination. Urban Growers Collective is reframing gardening as civic action.

Intermap's new automated service on Saudi-backed UP42 turns raw satellite imagery into analysis-ready data, a crucial move in the $429B space economy.

A massive acquisition, key exploration wins, and a state partnership have transformed Parex. We dissect the strategy behind its bold H2 2026 production goals.

Synagistics pairs its founder's vision with a new CEO's financial discipline. Is this the model for scaling AI and digital commerce across Asia's complex markets?

The Mass. Council on Economic Education endorses a new AP course, pushing for college-level financial literacy to become the new standard for all students.

IceCure's ProSense™ is reshaping oncology in Brazil. A US FDA approval provided a critical tailwind, validating a less invasive future for cancer care.

As the American Franchise Academy turns ten, we explore how it addresses a critical gap franchisors often miss: turning passionate operators into savvy CEOs.

Invivyd's COVID-19 drug PEMGARDA loses its emergency status, sparking a high-stakes race for full approval and raising fears of a looming gap in patient care.

VERAXA Biotech is betting its future on its proprietary BiTAC technology, a strategic pivot that sharpens its focus amid a volatile market for cancer therapies.

A South Korean biotech's diabetes drug finds new purpose in fighting FSHD, backed by a foundation's innovative funding model that could reshape rare disease R&D.